Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer

Molecular Cancer Therapeutics

Volumn 6, Issue 3, 2007, Pages 1039-1045

  Hassouneh, Basil ^a   Islam, Mozaffarul ^a   Nagel, Thomas ^a   Pan, Quintin ^a   Merajver, Sofia ^a   Teknos, Theodoros N ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; TETRATHIOMOLYBDIC ACID; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; LUNG METASTASIS; METASTASIS INHIBITION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME;

ADENOSINE TRIPHOSPHATASES; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL MOVEMENT; CERULOPLASMIN; DISEASE MODELS, ANIMAL; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; MICE; MICE, NUDE; MOLYBDENUM; NECROSIS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34147146006     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0524     Document Type: Article

References (40)

1. Folkman J. Fundamental concepts of the angiogenic process. Curr Mol Med 2003;3:643-51.
2. Harper J, Moses MA. Molecular regulation of tumor angiogenesis: mechanisms and therapeutic implications. EXS 2006;96:223-68.
3. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
4. Cao Y. Tumor angiogenesis and therapy. Biomed Pharmacother 2005; 59 Suppl 2:S340-3.
5. Sasano H, Suzuki T. Pathological evaluation of angiogenesis in human tumor. Biom Pharmacother 2005;59 Suppl 2:S334-6.
6. Neri D, Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005;5: 436-46.
7. Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev 2001;20:79-86.
8. Sweeney CJ, Miller KD, Sledge GW, Jr. Resistance in the anti-angiogenic era: nay-saying or a word of caution? Trends Mol Med 2003;9:24-9.
9. Longo R, Sarmiento R, Fanelli M, Capaccetti B, Gattuso D, Gasparini G. Anti-angiogenic therapy: rationale, challenges, and clinical studies. Angiogenesis 2002;5:237-56.
10. Gagne P, Akalu A, Brooks PC. Challenges facing antiangiogenic therapy for cancer: impact of the tumor extra cellular environment. Expert Rev Anticancer Ther 2004;4:129-40.
11. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9: 685-93.
12. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005;94:209-31.
13. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10.
14. Goodman VL, Brewer GJ, Merajver SD. Control of copper status for cancer therapy. Curr Cancer Drug Targets 2005;5:543-9.
15. Brewer GJ. Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease. Exp Biol Med (Maywood) 2001; 226:665-73.
16. Brewer GJ. Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer. Curr Cancer Drug Targets 2005;5: 195-202.
17. Pan Q, Kleer CG, van Golen KL, et al. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res 2002;62:4854-9.
18. Cox C, Merajver SD, Yoo S, et al. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch Otolaryngol Head Neck Surg 2003;129:781-5.
19. Teknos TN, Islam M, Arenberg DA, et al. The effect of tetrathiomolybdate on cytokine expression, angiogenesis, and tumor growth in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2005;131:204-11.
20. Brewer GJ. Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis, and inflammation. J Cell Mol Med 2003;7:11-20.
21. Brewer GJ. Anticopper therapy against cancer and diseases of inflammation and fibrosis. Drug Discov Today 2005;10:1103-9.
22. Cox C, Teknos TN, Barrios M, Brewer GJ, Dick RD, Merajver SD. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001;111:696-701.
23. Brewer GJ, Dick R, Zeng C, Hou G. The use of tetrathiomolybdate in treating fibrotic, inflammatory, and autoimmune diseases, including the non-obese diabetic mouse model. J Inorg Biochem 2006;100:927-30.
24. Elner SG, Elner VM, Yoshida A, Dick RD, Brewer GJ. Effects of tetrathiomolybdate in a mouse model of retinal neovascularization. Invest Ophthalmol Vis Sci 2005;46:299-303.
25. Vicari AP, Caux C. Chemokines in cancer. Cytokine Growth Factor Rev 2002;13:143-54.
26. Shemirani B, Crowe DL. Head and neck squamous cell carcinoma lines produce biologically active angiogenic factors. Oral Oncol 2000;36:61-6.
27. Teknos TN, Cox C, Barrios MA, et al. Tumor angiogenesis as a predictive marker for organ preservation in patients with advanced laryngeal carcinoma. Laryngoscope 2002;112:844-51.
28. Khan MK, Mamou F, Schipper MJ, et al. Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006;132: 333-8.
29. Kyzas PA, Cunha IW, Ioannidis JP. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis. Clin Cancer Res 2005;11: 1434-40.
30. Yuan A, Yang PC, Yu CJ, et al. Tumor angiogenesis correlates with histologic type and metastasis in non-small-cell lung cancer. Am J Respir Crit Care Med 1995;152:2157-62.
31. Pan Q, Bao LW, Merajver SD. Tetrathiomolybdate inhibits angiogenesis and metastasis through suppression of the NFκB signaling cascade. Mol Cancer Res 2003;1:701-6.
32. Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol 1981;107:703-10.
33. Schosinsky KH, Lehmann HP, Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by use of o-dianisidine dihydrochloride. Clin Chem 1974;20:1556-63.
34. Klein M, Picard E, Vignaud JM, et al. Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma. J Endo 1999;161:41-9.
35. Sen CK, Khanna S, Venojarvi M, et al. Copper-induced vascular endothelial growth factor expression and wound healing. Am J Physiol Heart Circ Physiol 2002;282:H1821-7.
36. Martin F, Linden T, Katschinski DM, et al. Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood 2005;105:4613-9.
37. Figueroa YG, Chan AK, Ibrahim R, et al. NF-κB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp Hematol 2002;30:1419-27.
38. Kim SH, Cho NH, Kim K, et al. Correlations of oral tongue cancer invasion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression. J Surg Oncol 2006;93:330-7.
39. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002;2:289-300.
40. 2+ stimulates matrix metalloproteinase-2 expression by fibroblast cultures. Life Sci 2000;67: 2257-65.